Author

Aundrietta D. Duncan

Iterion Therapeutics (United States)ORCID 0000-0002-1094-4844Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Emily R. TheiseniD· 2 shared Galen C. RaskiD· 2 shared Ariunaa BayanjargaliD· 1 shared Bingcong XiongiD· 1 shared Cenny TaslimiD· 1 shared Ciara Curran· 1 shared Colin NixoniD· 1 shared E. John TokarskyiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Emily R. TheisenORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 16, 2026

Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma

Toshiyasu Suzuki, Ciara Curran, Thomas M Drake…·Thomas Graham Bird

This study evaluates Tegavivint's efficacy and safety in Wnt-activated HCC, showing potent anti-tumour activity and safety in preclinical models.

DOI 10.64898/2026.07.14.738585

mousebulk RNA-seq

Pharmacology & ToxicologybioRxivPreprintJun 20, 2025

N'-(1-phenylethylidene)-benzohydrazide cytotoxicity is LSD1 independent and linked to Fe-S cluster disruption in Ewing sarcoma

John William Sherman, Galen C. Rask, Bingcong Xiong…·Emily R. Theisen

This paper identifies that SP-2509 and SP-2577, LSD1 inhibitors, induce cell death in Ewing sarcoma through Fe-S cluster disruption, independent of LSD1 inhibition.

DOI 10.1101/2025.06.20.660795

humanproteomics

Cancer BiologybioRxivPreprintMay 19, 2024

Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins

Galen C. Rask, Cenny Taslim, Ariunaa Bayanjargal…·Emily R. Theisen

This study shows seclidemstat inhibits the transcriptional activity of multiple FET fusion oncoproteins in vitro, suggesting it as a promising treatment for FET-rearranged sarcomas.

3 citations

humanbulk RNA-seq